ANAB 8-K
Anaptysbio, Inc (ANAB)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
Exhibit Title or Description |
Press release issued by AnaptysBio, Inc. regarding its financial results for the three months ended March 31, 2026, dated May 12, 2026. |
|
104 |
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
AnaptysBio, Inc. |
|
|
|
|
Date: |
May 12, 2026 |
By: |
/s/Christopher M. Murphy |
|
|
|
Name: Christopher M. Murphy |
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, CA — May 12, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
“Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and delivering an EBIT margin greater than 95%,” said Daniel Faga, president and chief executive officer. “With Chris Murphy joining as CFO, who brings deep business development and investment banking experience, our priority continues to be to protect our two royalty streams and return their value to shareholders.”
GSK Jemperli Financial Collaboration
Vanda Imsidolimab Financial Collaboration
Recent Leadership and Board of Directors Appointments
Stock Repurchase Plan
First Quarter Financial Results
About AnaptysBio
Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to whether Anaptys is able to protect its financial collaborations; and its ability to return value to its shareholders. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to protect its financial collaborations and return value to its shareholders, the company’s ability to operate efficiently with a limited staff, and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
This press release also includes a reference to EBIT margin which is a measure not presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which Anaptys believes provides important perspective with respect to operational profitability. Non-GAAP financial measures may exclude items that are significant in understanding and assessing Anaptys’ financial results, should not be considered in isolation or as an alternative to GAAP measures, and should be considered only as a supplement to, and not as superior to, GAAP measures. Anaptys cannot predict with certainty the magnitude or scope of certain items that would be included in the most directly comparable GAAP measure to EBIT margin for the relevant future periods, and such items may be significant. Due to these uncertainties, Anaptys cannot provide a quantitative reconciliation of EBIT margin to the most directly comparable GAAP financial measure without unreasonable effort.
Investor Contact:
Anaptys Investor Relations
_______________________________________
AnaptysBio, Inc.
Consolidated Balance Sheets
(in thousands, except par value data)
(unaudited)
|
|
March 31, 2026 |
|
|
December 31, 2025 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
248,469 |
|
|
$ |
238,196 |
|
Receivables from collaborative partners |
|
|
25,747 |
|
|
|
33,850 |
|
Short-term investments |
|
|
37,986 |
|
|
|
73,442 |
|
Prepaid expenses and other current assets |
|
|
3,907 |
|
|
|
4,762 |
|
Total current assets |
|
|
316,109 |
|
|
|
350,250 |
|
Property and equipment, net |
|
|
1,280 |
|
|
|
1,370 |
|
Operating lease right-of-use assets |
|
|
12,039 |
|
|
|
12,519 |
|
Other long-term assets |
|
|
256 |
|
|
|
256 |
|
Total assets |
|
$ |
329,684 |
|
|
$ |
364,395 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
7,517 |
|
|
$ |
3,871 |
|
Accrued expenses |
|
|
32,065 |
|
|
|
32,674 |
|
Current portion of operating lease liability |
|
|
2,120 |
|
|
|
2,080 |
|
Total current liabilities |
|
|
41,702 |
|
|
|
38,625 |
|
Liability related to sale of future royalties |
|
|
263,742 |
|
|
|
276,528 |
|
Operating lease liability, net of current portion |
|
|
11,493 |
|
|
|
12,032 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2026 and December 31, 2025, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value, 500,000 shares authorized, 29,031 shares and 28,019 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively |
|
|
29 |
|
|
|
28 |
|
Additional paid-in capital |
|
|
838,307 |
|
|
|
809,765 |
|
Accumulated other comprehensive loss |
|
|
(146 |
) |
|
|
(24 |
) |
Accumulated deficit |
|
|
(825,443 |
) |
|
|
(772,559 |
) |
Total stockholders’ equity |
|
|
12,747 |
|
|
|
37,210 |
|
Total liabilities and stockholders’ equity |
|
$ |
329,684 |
|
|
$ |
364,395 |
|
AnaptysBio, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
(unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Collaboration revenue |
|
$ |
25,556 |
|
|
$ |
27,771 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
33,991 |
|
|
|
41,180 |
|
General and administrative |
|
|
26,202 |
|
|
|
14,130 |
|
Total operating expenses |
|
|
60,193 |
|
|
|
55,310 |
|
Loss from operations |
|
|
(34,637 |
) |
|
|
(27,539 |
) |
Other income (expense), net: |
|
|
|
|
|
|
||
Interest income |
|
|
2,653 |
|
|
|
4,413 |
|
Non-cash interest expense for the sale of future royalties |
|
|
(20,859 |
) |
|
|
(18,061 |
) |
Other (expense) income, net |
|
|
(1 |
) |
|
|
1,902 |
|
Total other expense, net |
|
|
(18,207 |
) |
|
|
(11,746 |
) |
Loss before income taxes |
|
|
(52,844 |
) |
|
|
(39,285 |
) |
Provision for income taxes |
|
|
(40 |
) |
|
|
(44 |
) |
Net loss |
|
|
(52,884 |
) |
|
|
(39,329 |
) |
Other comprehensive loss: |
|
|
|
|
|
|
||
Unrealized loss on available-for-sale securities |
|
|
(122 |
) |
|
|
(144 |
) |
Comprehensive loss |
|
$ |
(53,006 |
) |
|
$ |
(39,473 |
) |
Net loss per common share: |
|
|
|
|
|
|
||
Basic and diluted |
|
$ |
(1.84 |
) |
|
$ |
(1.28 |
) |
Weighted-average number of shares outstanding: |
|
|
|
|
|
|
||
Basic and diluted |
|
|
28,691 |
|
|
|
30,644 |
|